MedTrace Logo

A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

NCT06263348 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2024

Last updated 2026-07-10

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.

Conditions

  • Type2diabetes

Interventions

DRUG

Dorzagliatin tablets

During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.

Sponsors & Collaborators

  • Kun Tuo Xincheng Pharmaceutical Researchand Development(Beijing)Co.,Ltd.

    collaborator UNKNOWN

  • Hua Medicine Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-17
Primary Completion
2025-12-31
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06263348 on ClinicalTrials.gov